Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 78

1.

Weight gain, metabolic disturbances, and physical health care in a Brazilian sample of outpatients with schizophrenia.

Gordon PC, Xavier JC, Louzã MR.

Neuropsychiatr Dis Treat. 2013;9:133-8. doi: 10.2147/NDT.S37019. Epub 2013 Jan 17.

PMID:
23355783
[PubMed]
Free PMC Article
2.

[Drawing up guidelines for the attendance of physical health of patients with severe mental illness].

Saravane D, Feve B, Frances Y, Corruble E, Lancon C, Chanson P, Maison P, Terra JL, Azorin JM; avec le soutien institutionnel du laboratoire Lilly.

Encephale. 2009 Sep;35(4):330-9. doi: 10.1016/j.encep.2008.10.014. Epub 2009 Jul 9. French.

PMID:
19748369
[PubMed - indexed for MEDLINE]
3.

[Metabolic side effects of risperidone in early onset schizophrenia].

Goeb JL, Marco S, Duhamel A, Kechid G, Bordet R, Thomas P, Delion P, Jardri R.

Encephale. 2010 Jun;36(3):242-52. doi: 10.1016/j.encep.2009.10.008. Epub 2009 Dec 1. French.

PMID:
20620267
[PubMed - indexed for MEDLINE]
4.

Management of antipsychotic-induced weight gain: prospective naturalistic study of the effectiveness of a supervised exercise programme.

Poulin MJ, Chaput JP, Simard V, Vincent P, Bernier J, Gauthier Y, Lanctôt G, Saindon J, Vincent A, Gagnon S, Tremblay A.

Aust N Z J Psychiatry. 2007 Dec;41(12):980-9.

PMID:
17999270
[PubMed - indexed for MEDLINE]
5.

Screening and Interventions for Childhood Overweight [Internet].

Whitlock EP, Williams SB, Gold R, Smith P, Shipman S.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2005 Jul.

PMID:
20722132
[PubMed]
Books & Documents
6.

[Clinical factors related to gains in body mass index (BMI) among patients under long-term antipsychotic treatment].

Koga M.

Seishin Shinkeigaku Zasshi. 2003;105(4):473-88. Japanese.

PMID:
12806910
[PubMed - indexed for MEDLINE]
7.

Metabolic syndrome in schizophrenia: a comparative study of antipsychotic-free/naïve and antipsychotic-treated patients from India.

Pallava A, Chadda RK, Sood M, Lakshmy R.

Nord J Psychiatry. 2012 Jun;66(3):215-21. doi: 10.3109/08039488.2011.621977. Epub 2011 Oct 24.

PMID:
22017264
[PubMed - indexed for MEDLINE]
8.

Metabolic syndrome among persons with schizophrenia and other psychotic disorders in a general population survey.

Suvisaari JM, Saarni SI, Perälä J, Suvisaari JV, Härkänen T, Lönnqvist J, Reunanen A.

J Clin Psychiatry. 2007 Jul;68(7):1045-55.

PMID:
17685741
[PubMed - indexed for MEDLINE]
9.

Comparing tolerability of olanzapine in schizophrenia and affective disorders: a meta-analysis.

Moteshafi H, Zhornitsky S, Brunelle S, Stip E.

Drug Saf. 2012 Oct 1;35(10):819-36. doi: 10.2165/11631510-000000000-00000.

PMID:
22967188
[PubMed - indexed for MEDLINE]
10.

Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents.

Schneiderhan ME, Batscha CL, Rosen C.

Pharmacotherapy. 2009 Aug;29(8):975-87. doi: 10.1592/phco.29.8.975.

PMID:
19637951
[PubMed - indexed for MEDLINE]
12.

Metabolic risk during antipsychotic treatment.

Newcomer JW.

Clin Ther. 2004 Dec;26(12):1936-46. Review.

PMID:
15823759
[PubMed - indexed for MEDLINE]
13.

The METEOR study: frequency of metabolic disorders in patients with schizophrenia. Focus on first and second generation and level of risk of antipsychotic drugs.

Falissard B, Mauri M, Shaw K, Wetterling T, Doble A, Giudicelli A, De Hert M.

Int Clin Psychopharmacol. 2011 Nov;26(6):291-302. doi: 10.1097/YIC.0b013e32834a5bf6.

PMID:
21876442
[PubMed - indexed for MEDLINE]
14.

[Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].

Ruetsch O, Viala A, Bardou H, Martin P, Vacheron MN.

Encephale. 2005 Jul-Aug;31(4 Pt 1):507-16. Review. French.

PMID:
16389718
[PubMed - indexed for MEDLINE]
15.

Identification, evaluation, and management of obesity in an academic primary care center.

O'Brien SH, Holubkov R, Reis EC.

Pediatrics. 2004 Aug;114(2):e154-9.

PMID:
15286251
[PubMed - indexed for MEDLINE]
16.

Physical health monitoring of patients with schizophrenia.

Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S.

Am J Psychiatry. 2004 Aug;161(8):1334-49. Review.

PMID:
15285957
[PubMed - indexed for MEDLINE]
17.

Prevalence of metabolic syndrome among Australians with severe mental illness.

John AP, Koloth R, Dragovic M, Lim SC.

Med J Aust. 2009 Feb 16;190(4):176-9.

PMID:
19220180
[PubMed - indexed for MEDLINE]
18.

Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.

Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, Friis S, Opjordsmoen S, Andreassen OA.

J Clin Psychopharmacol. 2008 Apr;28(2):132-7. doi: 10.1097/JCP.0b013e318166c4f7.

PMID:
18344722
[PubMed - indexed for MEDLINE]
19.

Prevalence and predictors of metabolic syndrome among patients attending an outpatient clozapine clinic in Australia.

Brunero S, Lamont S, Fairbrother G.

Arch Psychiatr Nurs. 2009 Jun;23(3):261-8. doi: 10.1016/j.apnu.2008.06.007. Epub 2009 Jan 15.

PMID:
19446781
[PubMed - indexed for MEDLINE]
20.

Low prevalence of obesity and metabolic syndrome in never-treated chronic schizophrenia.

Padmavati R, McCreadie RG, Tirupati S.

Schizophr Res. 2010 Aug;121(1-3):199-202. doi: 10.1016/j.schres.2010.05.010. Epub 2010 Jun 9.

PMID:
20538429
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk